SEC Form 4 · accession 0000899243-16-036180
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael J. Ambrogi
Officer — Chief Operating Officer
Period of report
Dec 19, 2016
Accepted (ET)
Dec 21, 2016 · 4:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Dec 19, 2016 | S | 20,000 | $8.7589 | D | 179,084 | D | |
| Ordinary SharesF2 | Dec 20, 2016 | S | 20,000 | $8.6238 | D | 159,084 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On December 19, 2016, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 20,000 shares in multiple trades at prices ranging from $8.55 to $9.05. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F2On December 20, 2016, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 20,000 shares in multiple trades at prices ranging from $8.525 to $8.80. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.